The Nucleic acid-based therapeutics market size was USD 5.01 Billion in 2023 and is expected to reach USD 14.98 Billion by 2032 and grow at a CAGR of 12.93 % over the forecast period of 2024-2032. The Nucleic Acid-based Therapeutics Market report provides in-depth statistical insights and emerging trends shaping the industry. It analyzes production capacity and utilization by country and type, along with raw material price fluctuations impacting manufacturing costs. The report examines regulatory developments influencing PE foam applications and explores sustainability metrics, including recycling rates and bio-based foam adoption. Additionally, it highlights innovation and R&D investments driving advancements in lightweight and high-performance PE foams. Lastly, the report tracks market demand trends across key end-use industries such as automotive, packaging, and construction.
Get more information on Nucleic Acid-based Therapeutics Market - Request Sample Report
Drivers
Rising demand for personalized medicine which drives market growth.
The growing demand for personalized medicine owing to the ability of these therapies to attract a specific treatment to the unique genetic profile of an individual. Nucleic acid-based therapeutics, such as mRNA therapies, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA) facilitate precision medicine by targeting the underlying pathogenesis of genetic disorders and chronic diseases, a breakthrough from traditional one-size-fits-all treatments. Novel genomics sequencing techniques and expected biomarker discovery may allow the design of therapies that target only the defective genes responsible, minimizing off-target effects and maximizing patient benefit. Enormous funding is being bestowed for precision medicine initiatives such as the U.S. Precision Medicine Initiative as well as the 1+ Million Genomes Project in Europe, further driving the market expansion. Moreover, custom RNA-based medicines for cancer, rare genetic diseases, and neurodegenerative diseases are released by pharmaceutical companies that amplify the adoption of nucleic acid-based gain. The nucleic acid-based therapeutics market is projected to grow further, driven by technological progress and rapid regulatory approvals amid a rising demand for personalized medicine.
Restraint
High cost associated with the nucleic acid-based therapeutics which may hamper the market growth.
It is due to their complicated manufacturing processes, advanced delivery systems, and large-scale clinical trial that make market accessibility difficult. Currently, nucleic acid-based therapies–including gene therapies, mRNA vaccines, and antisense oligonucleotides (ASOs)–utilize advanced technology pipelines such as CRISPR, lipid nanoparticles (LNPs), and viral/non-viral vectors that are costly to manufacture, which is not the case for traditional drugs. Then again, R&D expenditures are huge, with firms pouring an enormous amount of cash into creating thoroughly safe sound, and efficient formulations, frequently with no guarantee of approval from regulators. Besides, the decentralized scalability of nucleic acid-based drug production and the requirement for specialized storage and distribution infrastructure further add to costs. Although some costs are being subsidized through government-funded reimbursement programs, the expensive price tag continues to be a significant factor that prevents more widespread adoption and could ultimately hinder market growth.
Opportunity
Advancements in gene editing technologies create an opportunity in the market.
These technologies enable scientists to fix genetic mutations right at the level of DNA and should yield cures for inherited disorders, cancer, and other rare genetic diseases. Meanwhile, the gradual approvals of gene-editing therapies gave additional justification to their commercial prospective. In addition, developments in base editing and prime editing are rendering these gene therapies more efficient and with lower off-target effects, bringing them within a broader, more clinically relevant set of applications. Propelled by growing government support, including NIH funds for genome-editing research and the European Union allocating funding for CRISPR-based therapies, the market is poised for rapid growth. Gene editing will become more precise and more widely available, leading to more treatment options, fueling new pharmaceutical innovations, and creating more space for strategies to guide the development of precise and effective nucleic acid-based therapeutics.
Challenges
Limited drug delivery efficiency may challenge the market growth.
One of the significant challenges faced by the Nucleic Acid-based Therapeutics market is the supply chain disruptions and logistics challenges that have resulted in the unavailability of raw materials, production schedules, and the overall growth of the market. Disruption in the supply of polyethylene resins global ambiguities like geostrategic conflicts, trade barriers, and unstable crude oil rates have led to the disruption of PE foam grade polyethylene resins, which serves, as the major beginning material for producing PE foam. Furthermore, transportation delays, labor shortages as well as high freight costs are directly affecting the fast and effective delivery of PE foams among the end-use industries including packaging, automotive, and building & construction. This appears to have led a lot of manufacturers to regionalize sourcing strategies and optimize supply chains. Production has seemingly responded well, with fresh production being added to the market but logistical constraints remain and continue to destabilize prices and impact the timely matching of demand.
By Technology
RNA-targeted therapeutics held the largest market share around 35% in 2023. It is owing to a wide range of therapeutic applications, improving RNA technology, and successful commercialization of RNA-based drugs. The introduction of mRNA vaccines, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA) therapies has changed the way we face infectious diseases, genetic disorders, and cancers. Compared to DNA gene therapies, which offer permanent changes to the genome, RNA-based drugs can achieve a reversible genetic outcome, limiting adverse effects seen with long-lasting changes to DNA itself. Technological advancements, including lipid nanoparticle (LNP) delivery systems, coupled with synthetic RNA modifications, have further enhanced the functional stability of these therapeutics.
By Application
Cancer held the largest market share around 32% in 2023. the rising incidence of several cancer types and greater adoption of RNA-based therapies, gene silencing approaches, and targeted cancer immunotherapy increased demand for these products. Cancer is among the leading causes of death around the world, killing around 10 million people in 2022 alone, according to the World Health Organization (WHO). Motivated by the need for personalized and precision medicine, nucleic-acid-based drugs including mRNA-based cancer vaccines, antisense oligonucleotides (ASOs), and small interfering RNA therapies that target specific cancer-related genetic alterations have been developed and are becoming more available. These factors include the increasing number of clinical trials and investments in cancer research, and advancements in the lipid nanoparticle (LNP) delivery systems, which further boosted the dominancy of the cancer segment. Thanks to the development of gene-editing technologies such as CRISPR, nucleic acid-based therapeutics will further become a dominant force in cancer treatments.
By End Use Industry
The hospitals & clinics held the largest market share around 54% in 2023. The provision of necessary healthcare infrastructure, and rising penetration of precision medicine. Capitalizing on these advanced molecular diagnostics, genetic analysis tools, and a highly qualified workforce, these healthcare facilities seamlessly enable the rapid delivery of RNA-based therapeutics, gene-editing interventions, and antisense oligonucleotide (ASO) vectors for oncology, genetic diseases, and auto-inflammatory conditions. Moreover, hospitals and clinics account for the wellspring of clinical trials, and of FDA-approved therapies, assuring that patients receive the latest in nucleic acid-based therapeutic strategies. The rising incidence rate of chronic and rare diseases is again a major factor in the worldwide growth of personalized medicine and gene-based therapies which are still best practiced within treatment centers, such as hospitals & clinics. Furthermore, these advanced therapies are integrated with hospital treatment protocols as the government funding and reimbursement policies in developed countries tend to support the integration of advanced therapies into treatment protocols in hospitals.
Get Customized Report as per your Business Requirement - Request For Customized Report
North America held the largest market share around 46% in 2023. The Nucleic Acid-based Therapeutics Market was dominated by North America, led by the high biotechnology industry, improved healthcare infrastructure, and notable commitment to genomic medicine. Many of the world’s top pharma and biotech companies have come to call this region home including Moderna, Pfizer, Biogen, and Alnylam Pharmaceuticals which have made their greatest advances with mRNA vaccines, gene therapies, and RNA-based drugs. Moreover, the proximity to leading research institutes, government funding initiatives, and regulatory agencies provides rapid approval of these nucleic acid-based therapies. In addition, the high recurrence of cancer, genetic disorders, and infectious diseases in North America, along with a robust reimbursement framework and patient access to advanced therapies, has propelled this region to the market leader position. As North America continues to dominate the sector in terms of clinical trials, drug approvals, and investments in biopharmaceuticals, it is likely to continue as the leading continent for the nucleic acid-based therapeutics market.
Asia Pacific held a significant market share in 2023. increasing number of clinical trials in the region are some of the factors boosting the market. Thus, the Asia-Pacific region dominated the Nucleic Acid-based Therapeutics Market with a significant market share. The European Union (EU) and Region UK and US market due to support by the gov. from many countries particularly China, Japan, South Korea and India, has progressed greatly through gene therapy, RNA-based drugs, and mRNA vaccine developers because of the policy of financial support, manpower and the policy of regulation. China's "Made in China 2025" and Japan's AMED (Japan Agency for Medical Research and Development) have boosted R&D in the fields of genetic medicine and biopharmaceuticals, among other areas. In addition, the significant patient pool along with the high prevalence of cancer, genetic disorders, and infectious diseases in the Asia Pacific region has resulted in increased demand for advanced nucleic acid-based therapies.
Alnylam Pharmaceuticals (Onpattro, Givlaari)
Ionis Pharmaceuticals (Spinraza, Tegsedi)
Moderna Inc. (mRNA-1273, mRNA-1647)
BioNtech SE (BNT162b2, BNT111)
Sarepta Therapeutics (Exondys 51, Vyondys 53)
Wave Life Sciences (WVE-120101, WVE-120102)
Arrowhead Pharmaceuticals (ARO-AAT, ARO-HBV)
Dicerna Pharmaceuticals (Nedosiran, Belcesiran)
Translate Bio (MRT5005, MRT5201)
ProQR Therapeutics (Sepofarsen, QR-421a)
Stoke Therapeutics (STK-001, STK-002)
Silence Therapeutics plc (SLN360, SLN124)
Arcturus Therapeutics (ARCT-810, ARCT-021)
Regulus Therapeutics (RG-012, RGLS4326)
Voyager Therapeutics (VY-AADC, VY-HTT01)
Avidity Biosciences (del-brax, AOC 1001)
Akcea Therapeutics (Waylivra, Tegsedi)
Aro Biotherapeutics (Centyrin-siRNA Conjugates, ABX1100)
CureVac AG (CVnCoV, CV7202)
eTheRNA Immunotherapies (TriMix, ECI-006)
In December 2024, Ionis received FDA approval for Tryngolza (olezarsen), its first independently launched drug in 35 years, designed to treat familial chylomicronemia syndrome (FCS).
In October 2024, Wave Life Sciences announced positive interim results from a mid-stage trial of its Duchenne muscular dystrophy treatment, WVE-N531, demonstrating significant dystrophin expression in patients.
In September 2023, Aldevron collaborated with Integrated DNA Technologies to provide essential CRISPR components for cell and gene therapy developers, aiming to speed up therapeutic advancements.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 5.01 Billion |
| Market Size by 2032 | US$ 14.98 Billion |
| CAGR | CAGR of 12.93 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology (RNA targeted therapeutics, Gene therapies, Epigenetic and micro-RNA modulating therapies, Genome editing therapies, and Others) • By End-user (Hospitals & Clinics, Academic & Research Institutes, and Others) • By Application (Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Moderna Inc., BioNTech SE, Sarepta Therapeutics, Wave Life Sciences, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Translate Bio, ProQR Therapeutics, Stoke Therapeutics, Silence Therapeutics, Arcturus Therapeutics, Regulus Therapeutics, Voyager Therapeutics, Avidity Biosciences, Akcea Therapeutics, Aro Biotherapeutics, CureVac AG, eTheRNA Immunotherapies |
Ans: The Nucleic Acid-based Therapeutics Market was valued at USD 5.01 Billion in 2023.
Ans: The expected CAGR of the global Nucleic Acid-based Therapeutics Market during the forecast period is 12.93%
Ans: Hospitals & Clinics will grow rapidly in the Nucleic Acid-based Therapeutics Market from 2024-2032.
Ans: Rising demand for personalized medicine which drives market growth.
Ans: North America led the Nucleic Acid-based Therapeutics Market in the region with the highest revenue share in 2023.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 By Production Capacity and Utilization, by Country, By Type, 2023
5.2 Feedstock Prices, by Country, By Type, 2023
5.3 Regulatory Impact, by l Country, By Type, 2023.
5.4 Environmental Metrics: Emissions Data, Waste Management Practices, and Sustainability Initiatives, by Region
5.5 Innovation and R&D, Type, 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Nucleic Acid-based Therapeutics Market Segmentation, By Technology
7.1 Chapter Overview
7.2 RNA-targeted therapeutics
7.2.1 RNA-targeted therapeutics Market Trends Analysis (2020-2032)
7.2.2 RNA-targeted therapeutics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Gene therapies
7.3.1 Gene therapies Market Trends Analysis (2020-2032)
7.3.2 Gene therapies Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Epigenetic and microRNA modulating therapies
7.4.1 Epigenetic and microRNA modulating therapies Market Trends Analysis (2020-2032)
7.4.2 Epigenetic and microRNA modulating therapies Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Genome editing therapies
7.5.1 Genome editing therapies Market Trends Analysis (2020-2032)
7.5.2 Genome editing therapies Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.6.1 Others Market Trends Analysis (2020-2032)
7.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Nucleic Acid-based Therapeutics Market Segmentation, By Application
8.1 Chapter Overview
8.2 Autoimmune Disorders
8.2.1 Autoimmune Disorders Market Trends Analysis (2020-2032)
8.2.2 Autoimmune Disorders Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Infectious Diseases
8.3.1 Infectious Diseases Market Trends Analysis (2020-2032)
8.3.2 Infectious Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Genetic Disorders
8.4.1 Genetic Disorders Market Trends Analysis (2020-2032)
8.4.2 Genetic Disorders Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Cancer
8.5.1 Cancer Market Trends Analysis (2020-2032)
8.5.2 Cancer Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Nucleic Acid-based Therapeutics Market Segmentation, By End-Use Industry
9.1 Chapter Overview
9.2 Hospitals & Clinics
9.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Academic & Research Institutes
9.3.1 Academic & Research Institutes Market Trends Analysis (2020-2032)
9.3.2 Academic & Research Institutes Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.4 North America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.5 North America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.6.2 USA Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.6.3 USA Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.7.2 Canada Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.7.3 Canada Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.2.8.2 Mexico Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.2.8.3 Mexico Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.6.2 Poland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.6.3 Poland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.7.2 Romania Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.7.3 Romania Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.4 Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.5 Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.6.2 Germany Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.6.3 Germany Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.7.2 France Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.7.3 France Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.8.2 UK Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.8.3 UK Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.9.2 Italy Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.9.3 Italy Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.10.2 Spain Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.10.3 Spain Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.13.2 Austria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.13.3 Austria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.4 Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.5 Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.6.2 China Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.6.3 China Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.7.2 India Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.7.3 India Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.8.2 Japan Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.8.3 Japan Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.9.2 South Korea Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.9.3 South Korea Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.10.2 Vietnam Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.10.3 Vietnam Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.11.2 Singapore Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.11.3 Singapore Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.12.2 Australia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.12.3 Australia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.4 Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.5 Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.6.2 UAE Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.6.3 UAE Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.4 Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.5 Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.4 Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.5 Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.6.2 Brazil Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.6.3 Brazil Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.7.2 Argentina Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.7.3 Argentina Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.8.2 Colombia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.8.3 Colombia Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Technology (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By Application (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Nucleic Acid-based Therapeutics Market Estimates and Forecasts, By End-Use Industry (2020-2032) (USD Billion)
11. Company Profiles
11.1 Silence Therapeutics plc
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Ionis Pharmaceuticals
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Novartis
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Merck
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Arrowhead Pharmaceuticals
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 BioNtech
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 Pfizer Inc
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Protagonist Therapeutics, Inc
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Biomedica
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Moderna Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Technology
RNA-targeted therapeutics
Gene therapies
Epigenetic and microRNA modulating therapies
Genome editing therapies
Others
By Application
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
Others
By End Use Industry
Hospitals & Clinics
Academic & Research Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Cystic Fibrosis Market size was valued at USD 6.02 billion in 2023, and is expected to reach USD 10.85 billion by 2032, and grow at a CAGR of 6.83% over the forecast period 2024-2032.
The Veterinary Therapeutics Market size was valued at USD 43.58 Billion in 2023 and is projected to reach USD 82.40 Billion By 2032, Growing at a CAGR of 7.35% from 2024 to 2032.
The Dental 3D Printing Market size was USD 3.2 billion in 2023 and is projected to grow to USD 17.7 billion by 2032, with a CAGR of 21% during 2024-2032
The Urinary Incontinence Treatment Devices Market Size was valued at USD 3.15 billion in 2023 and is expected to reach USD 6.38 billion by 2032 and grow at a CAGR of 8.18% over the forecast period 2024-2032.
The Digestive Health Supplements Market Size was valued at USD 51.65 Billion in 2023 and is expected to reach USD 111.96 Billion by 2032 and grow at a CAGR of 9.42% over the forecast period 2024-2032.
The Pharmaceutical Excipients Market was valued at USD 9.5 Billion in 2023 and is expected to reach USD 17.8 million by 2032, growing at a CAGR of 7.2% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
